Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC Reply

被引：0
|
作者：
Cho, Byoung C. [1 ]
Sethi, Seema [2 ]
Spira, Alexander I. [3 ]
机构：
[1] Yonsei Univ, Coll Med, Seoul, South Korea
[2] Janssen Res & Dev, Spring House, PA USA
[3] Virginia Canc Specialists, Fairfax, VA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2025年 / 392卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：620 / 621
页数：2
相关论文
共 50 条
  • [41] CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC
    Zhou, Q.
    Wu, Y-L.
    Cheng, Y.
    Liu, Y.
    Chen, G.
    Cui, J.
    Yang, N.
    Song, Y.
    Li, X-L.
    Lu, S.
    Zhou, J.
    Ma, Z.
    Yu, S-Y.
    Huang, C.
    Shu, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
    Lee, Ki Hyeong
    Cho, Byoung Chul
    Ahn, Myung-Ju
    Lee, Yun-Gyoo
    Lee, Youngjoo
    Lee, Jong-Seok
    Kim, Joo-Hang
    Min, Young Joo
    Lee, Gyeong-Won
    Lee, Sung Sook
    Lee, Kyung-Hee
    Ko, Yoon Ho
    Shim, Byoung Yong
    Kim, Sang-We
    Shin, Sang Won
    Choi, Jin-Hyuk
    Kim, Dong-Wan
    Cho, Eun Kyung
    Park, Keon Uk
    Kim, Jin-Soo
    Chun, Sang Hoon
    Wang, Jangyoung
    Choi, Seokyoung
    Kang, Jin Hyoung
    CANCER RESEARCH AND TREATMENT, 2024, 56 (01): : 48 - 60
  • [43] MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab plus Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
    Shreeve, S. M.
    Martinez, M.
    Verheijen, R. B.
    Xie, J.
    Sun, T.
    Haddish-Berhane, N.
    Curtin, J. C.
    Karkera, J.
    Pang, D.
    Roshak, A.
    Knoblauch, R. E.
    Patel, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S620 - S621
  • [44] FDA approval of Amivantamab-Vmjw in combination with carboplatin and pemetrexed for EGFR-mutated NSCLC: a new therapeutic milestone
    Hassan, Ibrahim Nagmeldin
    Ibrahim, Muhsin Nagmeldin Hassan
    ANNALS OF MEDICINE AND SURGERY, 2025, 87 (03): : 1111 - 1113
  • [45] Osimertinib in untreated EGFR-mutated advanced lung adenocarcinoma: real world data
    Almusarhed, Manar
    Rehman, Faisal
    Chen, Ryan
    Ahmed, Samreen
    LUNG CANCER, 2023, 178 : S33 - S33
  • [46] EGFR-mutated NSCLC: A roadmap to treatment sequences
    Girard, Nicolas
    MED, 2024, 5 (09): : 1044 - 1047
  • [47] Resistance landscape to almonertinib in EGFR-mutated NSCLC
    Tian, M.
    Lu, Z.
    Chen, S.
    Lu, G.
    Bu, F.
    Deng, W.
    Ding, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1017 - S1017
  • [48] The efficacy and safety of furmonertinib in patients with advanced EGFR-mutated NSCLC and leptomeningeal metastases
    Han, Huan
    Tang, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Quality of Life in Long-Term Survivors with advanced EGFR-Mutated NSCLC
    Gijtenbeek, Rolof G. P.
    Bijlsma, Maria
    Damhuis, Ronald A. M.
    Van Der Wekken, Anthonie J.
    Stegmann, Mariken E.
    Buiter, Anne-Marije
    Reitsma, Bennie H.
    Staal-Van Brekel, Jeske A.
    Groen, Harry J. M.
    Van Geffen, Wouter H.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [50] Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
    Lim, Sun Min
    Tan, Jiunn-Liang
    Dias, Josiane Mourao
    Voon, Pei Jye
    How, Soon Hin
    Zhou, Xiangdong
    Xiong, Hailin
    Massuti, Bartomeu
    Medley, Louise C.
    Nagasaka, Misako
    Vicente, David
    Girard, Nicolas
    Rittmeyer, Achim
    Botesteanu, Dana-Adriana
    Alhadab, Ali
    Mahoney, Janine M.
    Zhang, Jie
    Bauml, Joshua Michael
    Baig, Mahadi
    Scott, Susan Combs
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8612 - LBA8612
12345